Differences in central pressure and arterial stiffness of moderate hypertensive patients treated with olmesartan plus amlodipine or lercanidipine at equal peripheral blood pressure values

Introduction: The combination of an angiotensin II receptor inhibitor (ARBs) and calcium channel blocker (CCB) is very common and effective in the treatment of high blood pressure (HTA) However, there is little data on the best possible combination, regarding systolic and diastolic blood pressures (SBPC, DBPC) and arterial rigidity . In this work, we evaluated the effect of an combined with one of two widely used CCBs in daily practice. Objectives: To study the effect on the SBPC and DBPC as well as the arterial stiffness of the treatment with olmesartan associated to amlodipine or lercanidipine of patients (P) with moderate HTA at equal peripheral arterial pressures. Materials and Methods: We studied 160 patients (P) with moderate HTA (68 7 years, 90 women and 70 men), which we have divided into two groups: Group I: 78 P who received olmesartan 40mg plus amlodipine (5-10 mg) and Group II: 82 P received olmesartan plus lercanidipine (10-20 mg) to keep the TA 140 / 80 mm Hg in office. In all, we measure the SBPC, DBPC, arterial stiffness measured by augmentation index (AI) at baseline and after 24 weeks of treatment (before-after). The results were compared and shown in the following table: e22 Abstracts / Journal of the American Soc